The role of the neuroprotective factor Npas4 in cerebral ischemia

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 29011-29028

  Choy, Fong Chan ^a   Klarić, Thomas S ^a   Koblar, Simon A ^a   Lewis, Martin D ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Apoptosis; Ischemic stroke; Neuroinflammation; Neuroprotection; Npas4

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IV; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIZOCILPINE; DNA BINDING PROTEIN; DOUBLECORTIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMATE RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NPAS4; TRANSCRIPTION FACTOR SOX2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; NPAS4 PROTEIN, HUMAN;

APOPTOSIS; BRAIN INJURY; BRAIN ISCHEMIA; CALCIUM SIGNALING; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CEREBELLUM GRANULAR LAYER; CHROMATIN IMMUNOPRECIPITATION; GENE SEQUENCE; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; IN SITU HYBRIDIZATION; LIMBIC SYSTEM; NERVE FUNCTION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; RECEPTOR UPREGULATION; REVIEW; SPREADING CORTICAL DEPRESSION; SYNAPTIC TRANSMISSION; TRANSCRIPTION REGULATION; UNTRANSLATED REGION; ANIMAL; BRAIN; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; NERVE CELL; PATHOLOGY;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN; BRAIN ISCHEMIA; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; NEURONS;

EID: 84949426275     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226144     Document Type: Review

References (120)

1. Donnan, G.A.; Fisher, M.; Macleod, M.; Davis, S.M. Stroke. Lancet 2008, 371, 1612–1623. [CrossRef]
2. Go, A.S.; Mozaffarian, D.; Roger, V.L.; Benjamin, E.J.; Berry, J.D.; Blaha, M.J.; Dai, S.; Ford, E.S.; Fox, C.S.; Franco, S., et al. Heart disease and stroke statistics-2014 update: A report from the american heart association. Circulation 2014, 129, E28–E292. [CrossRef] [PubMed]
3. Gonzalez, R. Imaging-guided acute ischemic stroke therapy: From “time is brain” to “physiology is brain”. Am. J. Neuroradiol. 2006, 27, 728–735. [PubMed]
4. Flood, W.D.; Moyer, R.W.; Tsykin, A.; Sutherland, G.R.; Koblar, S.A. Nxf and fbxo33: Novel seizure-responsive genes in mice. Eur. J. Neurosci. 2004, 20, 1819–1826. [CrossRef] [PubMed]
5. Ooe, N.; Saito, K.; Mikami, N.; Nakatuka, I.; Kaneko, H. Identification of a novel basic helix-loop-helix-pas factor, NXF, reveals a Sim2 competitive, positive regulatory role in dendritic-cytoskeleton modulator drebrin gene expression. Mol. Cell. Biol. 2004, 24, 608–616. [CrossRef] [PubMed]
6. Moser, M.; Knoth, R.; Bode, C.; Patterson, C. LE-PAS, a novel Arnt-dependent HLH-PAS protein, is expressed in limbic tissues and transactivates the CNS midline enhancer element. Mol. Brain Res. 2004, 128, 141–149. [CrossRef] [PubMed]
7. Lin, Y.; Bloodgood, B.L.; Hauser, J.L.; Lapan, A.D.; Koon, A.C.; Kim, T.-K.; Hu, L.S.; Malik, A.N.; Greenberg, M.E. Activity-dependent regulation of inhibitory synapse development by Npas 4. Nature 2008, 455, 1198–1204. [CrossRef] [PubMed]
8. Bloodgood, B.L.; Sharma, N.; Browne, H.A.; Trepman, A.Z.; Greenberg, M.E. The activity-dependent transcription factor Npas4 regulates domain-specific inhibition. Nature 2013, 503, 121–125. [CrossRef] [PubMed]
9. Spiegel, I.; Mardinly, A.R.; Gabel, H.W.; Bazinet, J.E.; Couch, C.H.; Tzeng, C.P.; Harmin, D.A.; Greenberg, M.E. Npas4 regulates excitatory-inhibitory balance within neural circuits through cell-type-specific gene programs. Cell 2014, 157, 1216–1229. [CrossRef] [PubMed]
10. Pruunsild, P.; Sepp, M.; Orav, E.; Koppel, I.; Timmusk, T. Identification of cis-elements and transcription factors regulating neuronal activity-dependent transcription of human bdnf gene. J. Neurosci. 2011, 31, 3295–3308. [CrossRef] [PubMed]
11. Bibel, M.; Barde, Y.A. Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 2000, 14, 2919–2937. [CrossRef] [PubMed]
12. Huang, E.J.; Reichardt, L.F. Neurotrophins: Roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24, 677–736. [CrossRef] [PubMed]
13. Ramamoorthi, K.; Fropf, R.; Belfort, G.M.; Fitzmaurice, H.L.; McKinney, R.M.; Neve, R.L.; Otto, T.; Lin, Y. Npas4 regulates a transcriptional program in CA3 required for contextual memory formation. Science 2011, 334, 1669–1675. [CrossRef] [PubMed]
14. Yun, J.; Koike, H.; Ibi, D.; Toth, E.; Mizoguchi, H.; Nitta, A.; Yoneyama, M.; Ogita, K.; Yoneda, Y.; Nabeshima, T., et al. Chronic restraint stress impairs neurogenesis and hippocampus-dependent fear memory in mice: Possible involvement of a brain-specific transcription factor Npas 4. J. Neurochem. 2010, 114, 1840–1851. [CrossRef] [PubMed]
15. Ploski, J.E.; Monsey, M.S.; Tam, N.; DiLeone, R.J.; Schafe, G.E. The neuronal pas domain protein 4 (Npas4) is required for new and reactivated fear memories. PLoS ONE 2011, 6, e23760. [CrossRef] [PubMed]
16. Coutellier, L.; Beraki, S.; Ardestani, P.M.; Saw, N.L.; Shamloo, M. Npas4: A neuronal transcription factor with a key role in social and cognitive functions relevant to developmental disorders. PLoS ONE 2012, 7, e46604. [CrossRef] [PubMed]
17. Sklar, P.; Ripke, S.; Scott, L.J.; Andreassen, O.A.; Cichon, S.; Craddock, N.; Edenberg, H.J.; Nurnberger, J.I. Jr.; Rietschel, M.; Blackwood, D., et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ 4. Nat. Genet. 2011, 43, 977–983. [CrossRef] [PubMed]
18. Ebert, D.H.; Greenberg, M.E. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 2013, 493, 327–337. [CrossRef] [PubMed]
19. Floor, K.; Baroy, T.; Misceo, D.; Kanavin, O.J.; Fannemel, M.; Frengen, E. A 1 mb de novo deletion within 11q13.1q13.2 in a boy with mild intellectual disability and minor dysmorphic features. Eur. J. Med. Genet. 2012, 55, 695–699. [CrossRef] [PubMed]
20. Jaehne, E.J.; Klaric, T.S.; Koblar, S.A.; Baune, B.T.; Lewis, M.D. Effects of Npas4 deficiency on anxiety, depression-like, cognition and sociability behaviour. Behav. Brain Res. 2015, 281, 276–282. [CrossRef] [PubMed]
21. Leong, W.K.; Klaric, T.S.; Lin, Y.; Lewis, M.D.; Koblar, S.A. Upregulation of the neuronal Per-Arnt-Sim domain protein 4 (Npas4) in the rat corticolimbic system following focal cerebral ischemia. Eur. J. Neurosci. 2013, 37, 1875–1884. [CrossRef] [PubMed]
22. Shamloo, M.; Soriano, L.; von Schack, D.; Rickhag, M.; Chin, D.J.; Gonzalez-Zulueta, M.; Gido, G.; Urfer, R.; Wieloch, T.; Nikolich, K. Npas4, a novel helix-loop-helix pas domain protein, is regulated in response to cerebral ischemia. Eur. J. Neurosci. 2006, 24, 2705–2720. [CrossRef] [PubMed]
23. Hester, I.; McKee, S.; Pelletier, P.; Thompson, C.; Storbeck, C.; Mears, A.; Schulz, J.B.; Hakim, A.A.; Sabourin, L.A. Transient expression of Nxf, a bHLH-PAS transactivator induced by neuronal preconditioning, confers neuroprotection in cultured cells. Brain Res. 2007, 1135, 1–11. [CrossRef] [PubMed]
24. Ooe, N.; Motonaga, K.; Kobayashi, K.; Saito, K.; Kaneko, H. Functional characterization of basic helix-loop-helix-PAS type transcription factor NXF in vivo putative involvement in an “on demand” neuroprotection system. J. Biol. Chem. 2009, 284, 1057–1063. [CrossRef] [PubMed]
25. Zhang, S.-J.; Zou, M.; Lu, L.; Lau, D.; Ditzel, D.A.W.; Delucinge-Vivier, C.; Aso, Y.; Descombes, P.; Bading, H. Nuclear calcium signaling controls expression of a large gene pool: Identification of a gene program for acquired neuroprotection induced by synaptic activity. PLoS Genet. 2009, 5, e1000604. [CrossRef] [PubMed]
26. Choy, F.C.; Klaric, T.S.; Leong, W.K.; Koblar, S.A.; Lewis, M.D. Reduction of the neuroprotective transcription factor Npas4 results in increased neuronal necrosis, inflammation and brain lesion size following ischaemia. J. Cereb. Blood Flow Metab. 2015. [CrossRef]
27. Crews, S.T.; Fan, C.M. Remembrance of things pas: Regulation of development by bHLH-PAS proteins. Curr. Opin. Genet. Dev. 1999, 9, 580–587. [CrossRef]
28. Kewley, R.J.; Whitelaw, M.L.; Chapman-Smith, A. The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. Int. J. Biochem. Cell Biol. 2004, 36, 189–204. [CrossRef]
29. Guillemin, K.; Krasnow, M.A. The hypoxic response: Huffing and hifing. Cell 1997, 89, 9–12. [CrossRef]
30. Ryan, H.E.; Lo, J.; Johnson, R.S. Hif-1α is required for solid tumor formation and embryonic vascularization. Embo J. 1998, 17, 3005–3015. [CrossRef] [PubMed]
31. Lees, M.J.; Whitelaw, M.L. Multiple roles of ligand in transforming the dioxin receptor to an active basic helix-loop-helix/PAS transcription factor complex with the nuclear protein arnt. Mol. Cell. Biol. 1999, 19, 5811–5822. [CrossRef] [PubMed]
32. Michaud, J.L.; Rosenquist, T.; May, N.R.; Fan, C.M. Development of neuroendocrine lineages requires the bHLH-PAS transcription factor sim 1. Genes Dev. 1998, 12, 3264–3275. [CrossRef] [PubMed]
33. Chapman-Smith, A.; Whitelaw, M.L. Novel DNA binding by a basic helix-loop-helix protein—The role of the dioxin receptor pas domain. J. Biol. Chem. 2006, 281, 12535–12545. [CrossRef] [PubMed]
34. Fairman, R.; BeranSteed, R.K.; Handel, T.M. Heteronuclear (1H-, 13C, 15N) nmr assignments and secondary structure of the basic region-helix-loop-helix domain of E 47. Protein Sci. 1997, 6, 175–184. [CrossRef] [PubMed]
35. Nambu, J.R.; Lewis, J.O.; Wharton, K.A.; Crews, S.T. The drosophila single-minded gene encodes a helix-loop-helix protein that acts as a master regulator of CNS midline development. Cell 1991, 67, 1157–1167. [CrossRef]
36. Taylor, B.L.; Zhulin, I.B. Pas domains: Internal sensors of oxygen, redox potential, and light. Microbiol. Mol. Biol. Rev. 1999, 63, 479–506. [PubMed]
37. Reiszporszasz, S.; Probst, M.R.; Fukunaga, B.N.; Hankinson, O. Identification of functional domains of the aryl-hydrocarbon receptor nuclear translocator protein (ARNT). Mol. Cell. Biol. 1994, 14, 6075–6086. [CrossRef]
38. Hirose, K.; Morita, M.; Ema, M.; Mimura, J.; Hamada, H.; Fujii, H.; Saijo, Y.; Gotoh, O.; Sogawa, K.; FujiiKuriyama, Y. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Mol. Cell. Biol. 1996, 16, 1706–1713. [CrossRef] [PubMed]
39. Ooe, N.; Saito, K.; Kaneko, H. Characterization of functional heterodirner partners in brain for a bHLH-PAS factor NXF. Biochim. Biophys. Acta 2009, 1789, 192–197. [CrossRef] [PubMed]
40. Schoenhard, J.A.; Eren, M.; Johnson, C.H.; Vaughan, D.E. Alternative splicing yields novel BMAL2 variants: Tissue distribution and functional characterization. Am. J. Physiol. Cell Physiol. 2002, 283, C103–C114. [CrossRef] [PubMed]
41. Wenger, R.H. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002, 16, 1151–1162. [CrossRef] [PubMed]
42. Klaric, T.; Lardelli, M.; Key, B.; Koblar, S.; Lewis, M. Activity-dependent expression of neuronal PAS domain-containing protein 4 (Npas4a) in the develop zebrafish brain. Front. Neuroanat. 2014, 8, 148. [PubMed]
43. Isaacson, R.L. A fuzzy limbic system. Behav. Brain Res. 1992, 52, 129–131. [CrossRef]
44. Kotter, R.; Meyer, N. The limbic system—A review of its empirical foundation. Behav. Brain Res. 1992, 52, 105–127. [CrossRef]
45. Bachevalier, J.; Alvarado, M.C.; Malkova, L. Memory and socioemotional behavior in monkeys after hippocampal damage incurred in infancy or in adulthood. Biol. Psychiatry 1999, 46, 329–339. [CrossRef]
46. Bachevalier, J.; Malkova, L. The amygdala and development of social cognition: Theoretical comment on Bauman, Toscano, Mason, Lavenex, and Amaral (2006). Behav. Neurosci. 2006, 120, 989–991. [CrossRef] [PubMed]
47. Prentice, L.M.; de Tassigny, X.D.A.; McKinney, S.; de Algara, T.R.; Yap, D.; Turashvili, G.; Poon, S.; Sutcliffe, M.; Allard, P.; Burleigh, A., et al. The testosterone-dependent and independent transcriptional networks in the hypothalamus of Gpr54 and Kiss1 knockout male mice are not fully equivalent. BMC Genom. 2011, 12. [CrossRef] [PubMed]
48. Unfried, C.; Burbach, G.; Korf, H.-W.; von Gall, C. Melatonin receptor 1-dependent gene expression in the mouse pars tuberalis as revealed by cdna microarray analysis and in situ hybridization. J. Pineal Res. 2010, 48, 148–156. [CrossRef] [PubMed]
49. Yoshihara, S.-I.; Takahashi, H.; Nishimura, N.; Kinoshita, M.; Asahina, R.; Kitsuki, M.; Tatsumi, K.; Furukawa-Hibi, Y.; Hirai, H.; Nagai, T., et al. Npas4 regulates Mdm2 and thus Dcx in experience-dependent dendritic spine development of newborn olfactory bulb interneurons. Cell Rep. 2014, 8, 843–857. [CrossRef] [PubMed]
50. Klaric, T.S.; Thomas, P.Q.; Dottori, M.; Leong, W.K.; Koblar, S.A.; Lewis, M.D. A reduction in Npas4 expression results in delayed neural differentiation of mouse embryonic stem cells. Stem Cell Res. Ther. 2014, 5, 64. [CrossRef] [PubMed]
51. Bertolino, M.; Llinas, R.R. The central role of voltage-activated and receptor-operated calcium channels in neuronal cells. Annu. Rev. Pharmacol. Toxicol. 1992, 32, 399–421. [CrossRef] [PubMed]
52. Hardingham, G.E.; Bading, H. Nuclear calcium: A key regulator of gene expression. Biometals 1998, 11, 345–358. [CrossRef] [PubMed]
53. Hardingham, G.E.; Bading, H. The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003, 26, 81–89. [CrossRef]
54. Lanahan, A.; Worley, P. Immediate-early genes and synaptic function. Neurobiol. Learn. Mem. 1998, 70, 37–43. [CrossRef] [PubMed]
55. Ooe, N.; Kobayashi, K.; Motonaga, K.; Saito, K.; Kaneko, H. Dynamic regulation of bHLH-PAS-type transcription factor NXF gene expression and neurotrophin dependent induction of the transcriptional control activity. Biochem. Biophys. Res. Commun. 2009, 378, 761–765. [CrossRef] [PubMed]
56. Coba, M.P.; Valor, L.M.; Kopanitsa, M.V.; Afinowi, N.O.; Grant, S.G.N. Kinase networks integrate profiles of N-methyl-D-aspartate receptor-mediated gene expression in hippocampus. J. Biol. Chem. 2008, 283, 34101–34107. [CrossRef] [PubMed]
57. Zhang, S.-J.; Steijaert, M.N.; Lau, D.; Schuetz, G.; Delucinge-Vivier, C.; Descombes, P.; Bading, H. Decoding NMDA receptor signaling: Identification of genomic programs specifying neuronal survival and death. Neuron 2007, 53, 549–562. [CrossRef] [PubMed]
58. Madabhushi, R.; Gao, F.; Pfenning, A.R.; Pan, L.; Yamakawa, S.; Seo, J.; Rueda, R.; Phan, T.X.; Yamakawa, H.; Pao, P.-C. Activity-induced DNA breaks govern the expression of neuronal early-response genes. Cell 2015, 161, 1592–1605. [CrossRef] [PubMed]
59. Hande, K. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur. J. Cancer 1998, 34, 1514–1521. [CrossRef]
60. Carrion, A.M.; Link, W.A.; Ledo, F.; Mellstrom, B.; Naranjo, J.R. Dream is a Ca2+-regulated transcriptional repressor. Nature 1999, 398, 80–84. [PubMed]
61. Mellstroem, B.; Sahun, I.; Ruiz-Nuno, A.; Murtra, P.; Gomez-Villafuertes, R.; Savignac, M.; Oliveros, J.C.; Gonzalez, P.; Kastanauskaite, A.; Knafo, S., et al. Dream controls the on/off switch of specific activity-dependent transcription pathways. Mol. Cell. Biol. 2014, 34, 877–887. [CrossRef] [PubMed]
62. Lindblad-Toh, K.; Garber, M.; Zuk, O.; Lin, M.F.; Parker, B.J.; Washietl, S.; Kheradpour, P.; Ernst, J.; Jordan, G.; Mauceli, E., et al. A high-resolution map of human evolutionary constraint using 29 mammals. Nature 2011, 478, 476–482. [CrossRef] [PubMed]
63. Lunyak, V.V.; Rosenfeld, M.G. No rest for REST: REST/NRSF regulation of neurogenesis. Cell 2005, 121, 499–501. [CrossRef] [PubMed]
64. Bersten, D.C.; Wright, J.A.; McCarthy, P.J.; Whitelaw, M.L. Regulation of the neuronal transcription factor Npas4 by rest and micrornas. Biochim. Biophys. Acta 2014, 1839, 13–24. [CrossRef] [PubMed]
65. Dirnagl, U.; Iadecola, C.; Moskowitz, M.A. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci. 1999, 22, 391–397. [CrossRef]
66. Mitsios, N.; Gaffney, J.; Kumar, P.; Krupinski, J.; Kumar, S.; Slevin, M. Pathophysiology of acute ischaemic stroke: An analysis of common signalling mechanisms and identification of new molecular targets. Pathobiology 2006, 73, 159–175. [CrossRef] [PubMed]
67. Catsicas, M.; Pequignot, Y.; Clarke, P.G.H. Rapid onset of neuronal death induced by blockade of either axoplasmic-transport or action-potentials in afferent-fibers during brain-development. J. Neurosci. 1992, 12, 4642–4650. [PubMed]
68. Sherrard, R.M.; Bower, A.J. Role of afferents in the development and cell survival of the vertebrate nervous system. Clin. Exp. Pharmacol. Physiol. 1998, 25, 487–495. [CrossRef] [PubMed]
69. Bok, J.; Wang, Q.; Huang, H.; Green, S.H. CaMKII and CaMKIV mediate distinct prosurvival signaling pathways in response to depolarization in neurons. Mol. Cell. Neurosci. 2007, 36, 13–26. [CrossRef] [PubMed]
70. Papadia, S.; Stevenson, P.; Hardingham, N.R.; Bading, H.; Hardingham, G.E. Nuclear Ca2+ and the camp response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J. Neurosci. 2005, 25, 4279–4287. [CrossRef] [PubMed]
71. Herrmann, M.; Ehrenreich, H. Brain derived proteins as markers of acute stroke: Their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring. Restor. Neurol. Neurosci. 2003, 21, 177–190. [PubMed]
72. Matsushima, K.; Hogan, M.J.; Hakim, A.M. Cortical spreading depression protects against subsequent focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 1996, 16, 221–226. [CrossRef] [PubMed]
73. Matsushima, K.; Schmidt-Kastner, R.; Hogan, M.J.; Hakim, A.M. Cortical spreading depression activates trophic factor expression, in neurons and astrocytes and protects against subsequent focal brain ischemia. Brain Res. 1998, 807, 47–60. [CrossRef]
74. Lipsky, R.H.; Marini, A.M. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann. N. Y. Acad. Sci. 2007, 1122, 130–143. [CrossRef] [PubMed]
75. Ghosh, A.; Carnahan, J.; Greenberg, M.E. Requirement for bdnf in activity-dependent survival of cortical-neurons. Science 1994, 263, 1618–1623. [CrossRef] [PubMed]
76. Alderson, R.F.; Alterman, A.L.; Barde, Y.A.; Lindsay, R.M. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron 1990, 5, 297–306. [CrossRef]
77. Golstein, P.; Kroemer, G. Redundant cell death mechanisms as relics and backups. Cell Death Differ. 2005, 12, 1490–1496. [CrossRef] [PubMed]
78. Proskuryakov, S.Y.; Konoplyannikov, A.G.; Gabai, V.L. Necrosis: A specific form of programmed cell death? Exp. Cell Res. 2003, 283, 1–16. [CrossRef]
79. Brouns, R.; de Deyn, P.P. The complexity of neurobiological processes in acute ischemic stroke. Clin. Neurol. Neurosurg. 2009, 111, 483–495. [CrossRef] [PubMed]
80. Kreutzberg, G.W. Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 1996, 19, 312–318. [CrossRef]
81. Thomas, W.E. Brain macrophages: Evaluation of microglia and their functions. Brain Res. Rev. 1992, 17, 61–74. [CrossRef]
82. Wood, P.L. Microglia as a unique cellular target in the treatment of stroke: Potential neurotoxic mediators produced by activated microglia. Neurol. Res. 1995, 17, 242–248. [PubMed]
83. Zhang, N.; Komine-Kobayashi, M.; Tanaka, R.; Liu, M.Z.; Mizuno, Y.; Urabe, T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005, 36, 2220–2225. [CrossRef] [PubMed]
84. Gunther, A.; Kuppers-Tiedt, L.; Schneider, P.M.; Kunert, I.; Berrouschot, J.; Schneider, D.; Rossner, S. Reduced infarct volume and differential effects on glial cell activation after hyperbaric oxygen treatment in rat permanent focal cerebral ischaemia. Eur. J. Neurosci. 2005, 21, 3189–3194. [CrossRef] [PubMed]
85. Giulian, D.; Corpuz, M.; Chapman, S.; Mansouri, M.; Robertson, C. Reactive mononuclear phagocytes release neurotoxins after ischemic and traumatic injury to the central-nervous-system. J. Neurosci. Res. 1993, 36, 681–693. [CrossRef] [PubMed]
86. Lehnardt, S.; Massillon, L.; Follett, P.; Jensen, F.E.; Ratan, R.; Rosenberg, P.A.; Volpe, J.J.; Vartanian, T. Activation of innate immunity in the CNS triggers neurodegeneration through a toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. USA 2003, 100, 8514–8519. [CrossRef] [PubMed]
87. Denes, A.; Vidyasagar, R.; Feng, J.; Narvainen, J.; McColl, B.W.; Kauppinen, R.A.; Allan, S.M. Proliferating resident microglia after focal cerebral ischaemia in mice. J. Cereb. Blood Flow Metab. 2007, 27, 1941–1953. [CrossRef] [PubMed]
88. Nakajima, K.; Kohsaka, S. Microglia: Neuroprotective and neurotrophic cells in the central nervous system. Curr. Drug Targets Cardiovasc. Haematol. Disord. 2004, 4, 65–84. [CrossRef] [PubMed]
89. Streit, W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002, 40, 133–139. [CrossRef] [PubMed]
90. Zhao, Y.; Rempe, D.A. Targeting astrocytes for stroke therapy. Neurotherapeutics 2010, 7, 439–451. [CrossRef] [PubMed]
91. Pekny, M.; Nilsson, M. Astrocyte activation and reactive gliosis. Glia 2005, 50, 427–434. [CrossRef] [PubMed]
92. Hewett, S.J.; Muir, J.K.; Lobner, D.; Symons, A.; Choi, D.W. Potentiation of oxygen-glucose deprivation-induced neuronal death after induction of inos. Stroke 1996, 27, 1586–1591. [CrossRef] [PubMed]
93. Donohue, P.J.; Richards, C.M.; Brown, S.A.N.; Hanscom, H.N.; Buschman, J.; Thangada, S.; Hla, T.; Williams, M.S.; Winkles, J.A. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-a mitogenic activity. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 594–600. [CrossRef] [PubMed]
94. Yepes, M.; Brown, S.A.N.; Moore, E.G.; Smith, E.P.; Lawrence, D.A.; Winkles, J.A. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am. J. Pathol. 2005, 166, 511–520. [CrossRef]
95. Lakhan, S.E.; Kirchgessner, A.; Hofer, M. Inflammatory mechanisms in ischemic stroke: Therapeutic approaches. J. Transl. Med. 2009, 7, 97. [CrossRef] [PubMed]
96. Lucas, S.M.; Rothwell, N.J.; Gibson, R.M. The role of inflammation in cns injury and disease. Br. J. Pharmacol. 2006, 147, S232–S240. [CrossRef] [PubMed]
97. Yamashita, T.; Sawamoto, K.; Suzuki, S.; Suzuki, N.; Adachi, K.; Kawase, T.; Mihara, M.; Ohsugi, Y.; Abe, K.; Okano, H. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: Possible involvement of Stat3 activation in the protection of neurons. J. Neurochem. 2005, 94, 459–468. [CrossRef] [PubMed]
98. Berghe, T.V.; Linkermann, A.; Jouan-Lanhouet, S.; Walczak, H.; Vandenabeele, P. Regulated necrosis: The expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol. 2014, 15, 135–147. [CrossRef] [PubMed]
99. Chinenov, Y.; Kerppola, T.K. Close encounters of many kinds: Fos-jun interactions that mediate transcription regulatory specificity. Oncogene 2001, 20, 2438–2452. [CrossRef] [PubMed]
100. Wang, Y.; Prywes, R. Activation of the c-fos enhancer by the erk MAP kinase pathway through two sequence elements: The c-fos AP-1 and p62TCF sites. Oncogene 2000, 19, 1379–1385. [CrossRef] [PubMed]
101. Shafarenko, M.; Amanullah, A.; Gregory, B.; Liebermann, D.A.; Hoffman, B. Fos modulates myeloid cell survival and differentiation and partially abrogates the c-Myc block in terminal myeloid differentiation. Blood 2004, 103, 4259–4267. [CrossRef] [PubMed]
102. Appierto, V.; Villani, M.G.; Cavadini, E.; Lotan, R.; Vinson, C.; Formelli, F. Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ. 2004, 11, 270–279. [CrossRef] [PubMed]
103. Ray, N.; Kuwahara, M.; Takada, Y.; Maruyama, K.; Kawaguchi, T.; Tsubone, H.; Ishikawa, H.; Matsuo, K. c-Fos suppresses systemic inflammatory response to endotoxin. Int. Immunol. 2006, 18, 671–677. [CrossRef] [PubMed]
104. Baldwin, A.S. Jr. Series introduction: The transcription factor NF-KB and human disease. J. Clin. Investig. 2001, 107, 3. [CrossRef] [PubMed]
105. Thomasova, D.; Mulay, S.R.; Bruns, H.; Anders, H.-J. p53-independent roles of MDM2 in NF-κB signaling: Implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 2012, 14, 1097–1101. [CrossRef] [PubMed]
106. Colton, C.A. Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 2009, 4, 399–418. [CrossRef] [PubMed]
107. Nakagawa, Y.; Chiba, K. Role of microglial M1/M2 polarization in relapse and remission of psychiatric disorders and diseases. Pharmaceuticals 2014, 7, 1028–1048. [CrossRef] [PubMed]
108. Cherry, J.D.; Olschowka, J.A.; O’Banion, M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J. Neuroinflamm. 2014, 11, 98. [CrossRef] [PubMed]
109. O’Collins, V.E.; Macleod, M.R.; Donnan, G.A.; Horky, L.L.; van der Worp, B.H.; Howells, D.W. 1026 experimental treatments in acute stroke. Ann. Neurol. 2006, 59, 467–477. [PubMed]
110. Iadecola, C.; Anrather, J. The immunology of stroke: From mechanisms to translation. Nat. Med. 2011, 17, 796–808. [CrossRef] [PubMed]
111. Wang, X.K. Investigational anti-inflammatory agents for the treatment of ischaemic brain injury. Expert Opin. Investig. Drugs 2005, 14, 393–409. [CrossRef] [PubMed]
112. Yilmaz, G.; Granger, D.N. Cell adhesion molecules and ischemic stroke. Neurol. Res. 2008, 30, 783–793. [CrossRef] [PubMed]
113. Prestigiacomo, C.J.; Kim, S.C.; Connolly, E.S.; Liao, H.; Yan, S.F.; Pinsky, D.J. Cd18-mediated neutrophil recruitment contributes to the pathogenesis of reperfused but not nonreperfused stroke. Stroke 1999, 30, 1110–1116. [CrossRef] [PubMed]
114. Zhang, R.L.; Chopp, M.; Jiang, N.; Tang, W.X.; Prostak, J.; Manning, A.M.; Anderson, D.C. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the wistar rat. Stroke 1995, 26, 1438–1442. [CrossRef] [PubMed]
115. Zhang, L.; Zhang, Z.G.; Zhang, R.L.; Lu, M.; Krams, M.; Chopp, M. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 2003, 34, 1790–1795. [CrossRef] [PubMed]
116. Sherman, D.G.; Bes, A.; Easton, J.D.; Hacke, W.; Kaste, M.; Polmar, S.H.; Zivin, J.A.; Fieschi, C.; Miller, P.; Schoenfeld, D., et al. Use of anti-icam-1 therapy in ischemic stroke—Results of the enlimomab acute stroke trial. Neurology 2001, 57, 1428–1434.
117. Becker, K.J. Anti-leukocyte antibodies: Leukarrest (hu23f2g) and enlimomab (r6.5) in acute stroke. Curr. Med. Res. Opin. 2002, 18, s18–s22. [CrossRef] [PubMed]
118. Jin, R.; Liu, L.; Zhang, S.; Nanda, A.; Li, G. Role of inflammation and its mediators in acute ischemic stroke. J. Cardiovasc. Transl. Res. 2013, 6, 834–851. [CrossRef] [PubMed]
119. Patel, A.R.; Ritzel, R.; McCullough, L.D.; Liu, F. Microglia and ischemic stroke: A double-edged sword. Int. J. Physiol. Pathophysiol. Pharmacol. 2013, 5, 73–90. [PubMed]
120. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. [CrossRef] [PubMed]